Company news

Moderna, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV M...

April 5, 2023

Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

March 29, 2023

Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution

March 29, 2023

Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023

March 23, 2023

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

March 22, 2023

BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani

March 21, 2023

Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting

March 13, 2023

Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023

March 9, 2023

Moderna to Present at Cowen's 43rd Annual Health Care Conference

February 27, 2023

Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

February 22, 2023

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk...

February 21, 2023

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

February 21, 2023

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

February 16, 2023

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

February 15, 2023

Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023

February 1, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

January 29, 2023

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

January 16, 2023

Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

January 8, 2023

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

Moderna to Acquire OriCiro Genomics

January 3, 2023

Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

January 2, 2023

Moderna Finalizes Strategic Partnership with UK Government

December 20, 2022

Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial

December 19, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

December 15, 2022

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

December 12, 2022

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

December 7, 2022

Brad Miller Joins Moderna as Chief Information Officer

December 6, 2022

David Jiménez Joins Moderna As U.S. General Manager

November 16, 2022

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

November 13, 2022

Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

November 3, 2022

Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 2, 2022

Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries

October 16, 2022

Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022

October 12, 2022

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

October 11, 2022

Moderna Creates New Executive Committee Role Ahead of New Product Launches

September 28, 2022

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

September 27, 2022

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine

August 31, 2022

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older

August 30, 2022

Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

August 29, 2022

Moderna to Host R&D Day on Thursday, September 8, 2022

August 28, 2022

Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform

August 25, 2022

Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222

August 22, 2022

Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada

August 21, 2022

James Mock Joins Moderna as Chief Financial Officer

August 16, 2022

Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

August 7, 2022

Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 2, 2022

Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses

July 28, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

July 21, 2022

Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)

July 13, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 63 decks. Every deck is listed under its year.